Literature DB >> 32106418

Roles of Splicing Factors in Hormone-Related Cancer Progression.

Toshihiko Takeiwa1, Yuichi Mitobe1, Kazuhiro Ikeda1, Kuniko Horie-Inoue1, Satoshi Inoue1,2.   

Abstract

Splicing of mRNA precursor (pre-mRNA) is a mechanism to generate multiple mRNA isoforms from a single pre-mRNA, and it plays an essential role in a variety of biological phenomena and diseases such as cancers. Previous studies have demonstrated that cancer-specific splicing events are involved in various aspects of cancers such as proliferation, migration and response to hormones, suggesting that splicing-targeting therapy can be promising as a new strategy for cancer treatment. In this review, we focus on the splicing regulation by RNA-binding proteins including Drosophila behavior/human splicing (DBHS) family proteins, serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs) in hormone-related cancers, such as breast and prostate cancers.

Entities:  

Keywords:  DBHS family proteins; SR proteins; breast cancer; hnRNPs; prostate cancer

Year:  2020        PMID: 32106418     DOI: 10.3390/ijms21051551

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  8 in total

1.  [Construction of an adenovirus vector expressing engineered splicing factor for regulating alternative splicing of YAP1 in neonatal rat cardiomyocytes].

Authors:  Y Li; Q Zhao; X Song; J Song
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

2.  PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2.

Authors:  Toshihiko Takeiwa; Kazuhiro Ikeda; Takashi Suzuki; Wataru Sato; Kaori Iino; Yuichi Mitobe; Hidetaka Kawabata; Kuniko Horie; Satoshi Inoue
Journal:  Sci Rep       Date:  2022-06-09       Impact factor: 4.996

3.  Multiple Phosphorylations of SR Protein SRSF3 and Its Binding to m6A Reader YTHDC1 in Human Cells.

Authors:  Takanori Tatsuno; Yasuhito Ishigaki
Journal:  Cells       Date:  2022-04-26       Impact factor: 7.666

Review 4.  Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.

Authors:  Flavia Zita Francies; Rodney Hull; Richard Khanyile; Zodwa Dlamini
Journal:  Am J Cancer Res       Date:  2020-05-01       Impact factor: 5.942

Review 5.  Temperature-Dependent Alternative Splicing of Precursor mRNAs and Its Biological Significance: A Review Focused on Post-Transcriptional Regulation of a Cold Shock Protein Gene in Hibernating Mammals.

Authors:  Takahiko Shiina; Yasutake Shimizu
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

6.  Proteomic and Transcriptomic Analysis Identify Spliceosome as a Significant Component of the Molecular Machinery in the Pituitary Tumors Derived from POU1F1- and NR5A1-Cell Lineages.

Authors:  Keiko Taniguchi-Ponciano; Eduardo Peña-Martínez; Gloria Silva-Román; Sandra Vela-Patiño; Ana Laura Guzman-Ortiz; Hector Quezada; Erick Gomez-Apo; Laura Chavez-Macias; Sophia Mercado-Medrez; Guadalupe Vargas-Ortega; Ana Laura Espinosa-de-Los-Monteros; Baldomero Gonzales-Virla; Aldo Ferreira-Hermosillo; Etual Espinosa-Cardenas; Claudia Ramirez-Renteria; Ernesto Sosa; Blas Lopez-Felix; Gerardo Guinto; Daniel Marrero-Rodríguez; Moises Mercado
Journal:  Genes (Basel)       Date:  2020-11-27       Impact factor: 4.096

7.  Comprehensive analysis of aberrant alternative splicing related to carcinogenesis and prognosis of papillary thyroid cancer.

Authors:  Xiaobo Zheng; Li Feng; Yunfan Yin; Chune Yu; Xiujing He; Jiao Zhu; Ming Zhang; Jing Yu; Mingqing Xu
Journal:  Aging (Albany NY)       Date:  2021-10-08       Impact factor: 5.682

8.  Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer.

Authors:  Fangdie Ye; Yingchun Liang; Zhang Cheng; Yufei Liu; Jimeng Hu; Weijian Li; Xinan Chen; Jiahao Gao; Haowen Jiang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.